The company plans to appeal the order, which was issued in response to Eon’s motion for summary judgment without the benefit of a hearing.
Furthermore, the order is unrelated to the company’s pending litigation against Sandoz, successor to Eon, in the US District Court of New Jersey regarding an additional US patent relating to Skelaxin.
Importantly, Sandoz does not currently have an abbreviated new drug application approved by the FDA to market a generic version of Skelaxin.